背景:C-X-C基序趋化因子配体(CXCL8),白细胞介素8是一种典型的CXC家族趋化因子,带有谷氨酸-亮氨酸-精氨酸(ELR)基序,在人类一系列癌症的发生和发展中起关键作用。许多先前的研究集中在探索CXCL8基因多态性与癌症风险之间的关系。然而,其中许多报告的统计能力有限,在许多情况下产生模棱两可或冲突的结果。
方法:因此,PubMed,万方,使用关键字\'IL-8\'或\'白介素-8\'或\'CXCL8\'搜索Scopus和WebofScience数据库,查找直到2023年7月20日发表的文章,“多态性”和“癌症”或“肿瘤”。利用赔率比(ORs)和95%置信区间(CIs)检查相关性。用TaqMan测定评估CXCL8+781多态性基因型。
结果:为了更好地理解这些多态性与疾病风险之间的关联,进行了约29篇相关出版物。CXCL8-353A/T多态性与总体癌症风险增加相关[A与T,优势比(OR)=1.255,95%置信区间(CI)(1.079-1.459),P异质性=0.449,P=0.003]。CXCL8+781T/C等位基因与高加索人的癌症风险相似[TT与TC+CC,OR=1.320,95CI(1.046-1.666),异质性=0.375,P=0.019]。此外,与CC基因型相比,携带CXCL8+781TT+TC基因型的口腔癌患者血清CXCL8水平显着增加(P<0.01),与基因型匹配的正常对照相比,也显示出相似的趋势(P<0.01)。最后,几个限制,如纳入研究中可能存在发表偏倚或异质性,应引起重视.
结论:目前的研究表明,CXCL8-353和+781多态性可能与更高的癌症风险有关,这可能会影响癌症的预防,诊断,或通过CXCL8的不同表达进行治疗。同时,+781多态性可能进一步提供作为生物标志物的价值,有助于口腔癌的早期识别和预后评估.
BACKGROUND: C-X-C motif chemokine ligand (CXCL8), also known as interleukin-8, is a prototypical CXC family chemokine bearing a glutamic acid-leucine-arginine (ELR) motif that plays key roles in the onset and progression of a range of cancers in humans. Many prior studies have focused on exploring the relationship between CXCL8 gene polymorphisms and the risk of cancer. However, the statistical power of many of these
reports was limited, yielding ambiguous or conflicting results in many cases.
METHODS: Accordingly, the PubMed, Wanfang, Scopus and Web of Science databases were searched for articles published until July 20, 2023 using the keywords \'IL-8\' or \'interleukin-8\' or \'CXCL8\', \'polymorphism\' and \'cancer\' or \'tumor\'. Odds ratios (ORs) and 95% confidence intervals (CIs) were utilized to examine the association. The CXCL8 +781 polymorphism genotypes were assessed with a TaqMan assay.
RESULTS: About 29 related publications was conducted in an effort to better understand the association between these polymorphisms and disease risk. The CXCL8 -353A/T polymorphism was associated with an increased overall cancer risk [A vs. T, odds ratio (OR) = 1.255, 95% confidence interval (CI) (1.079-1.459), Pheterogeneity = 0.449, P = 0.003]. The CXCL8 +781 T/C allele was similarly associated with a higher risk of cancer among Caucasians [TT vs. TC + CC, OR = 1.320, 95%CI (1.046-1.666), Pheterogeneity = 0.375, P = 0.019]. Furthermore, oral cancer patients carrying the CXCL8 +781 TT + TC genotypes exhibited pronounced increases in serum levels of CXCL8 as compared to the CC genotype (P < 0.01), and also shown similar trend as compared to genotype-matched normal controls (P < 0.01). Finally, several limitations, such as the potential for publication bias or heterogeneity among the included studies should be paid attention.
CONCLUSIONS: Current study suggested that the CXCL8 -353 and +781 polymorphisms may be associated with a greater risk of cancer, which might impact cancer prevention, diagnosis, or treatment through the different expression of CXCL8. At the same time, the +781 polymorphism may further offer value as a biomarker that can aid in the early identification and prognostic evaluation of oral cancer.